Post hoc subgroup analysis of the ACORN trial and an instrumental variable study: white cell count modified the effect of cefepime vs piperacillin-tazobactam on 28-day mortality; in ACORN, WBC ≥16 favoured piperacillin-tazobactam (OR 0.51).
Secondary analysis
Rzewnicki et al. Association of white blood cell count with treatment response to cefepime versus piperacillin-tazobactam